Syncom Formulation (India) (NSE:SYNCOMF) Buildings And Improvements : ₹0 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Buildings And Improvements?

Syncom Formulation (India)'s annual buildings and improvements stayed the same from Mar. 2022 (₹343 Mil) to Mar. 2023 (₹343 Mil) but then declined from Mar. 2023 (₹343 Mil) to Mar. 2024 (₹0 Mil).

Syncom Formulation (India) Buildings And Improvements Historical Data

The historical data trend for Syncom Formulation (India)'s Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Buildings And Improvements Chart

Syncom Formulation (India) Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Buildings And Improvements

Get a 7-Day Free Trial

308.58

314.81

343.32

Syncom Formulation (India) Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial															343.32	-	-	-	-

Syncom Formulation (India) Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Buildings And Improvements

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines